All In Biotech

NDA 017707 · Ge Healthcare

Mpi Indium Dtpa In 111

Indium In-111 Pentetate Disodium · Intrathecal · Radioactive Diagnostic Agent

Novel

Last checked: Nov 19, 2026Latest source record: Dec 22, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Feb 18, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

6

0 Phase 3, 1 recruiting

FAERS reports

14

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 10, 2024.

INDICATIONS AND USAGE Pentetate Indium Disodium In 111 is recommended for use in radionuclide cisternography.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 18, 1982 Original approval · Type 1 - New Molecular Entity
1 products under this application
  • MPI INDIUM DTPA IN 111 · INDIUM IN-111 PENTETATE DISODIUM 1mCi/ML · INJECTABLE, INTRATHECAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Indium In-111 Pentetate Disodium" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • no adverse event13
  • drug ineffective8
  • radioisotope scan abnormal3
  • false positive investigation result2
  • meningitis1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20141
20152
20163
20191
20204
20233

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Ge Healthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.